Introduction
============

Osteomyelitis is a bacterial infection of the bone or bone marrow often resulting in hospital admission[@B1]. Osteomyelitis may result from contiguous spread of infection from adjacent soft tissues and joints, hematogenous seeding, or direct inoculation of bacteria into the bone as a result of trauma or surgery.

There has been a remarkable increase in osteomyelitis in the USA between 1969 and 2009 for reasons that remain unclear, but could comprise a variety of host, pathogen and environmental factors[@B2]. To date, little is known about changes in the epidemiological and clinical findings of osteoarticular infections over long periods of time. Conceivably, there may have been major changes in the microbiology, types of osteoarticular infections, and the characteristics of patients at risk. For example, the widespread use of medical devices in orthopaedic surgery and increased life expectancy of the population are all factors related to the increased rates of some osteoarticular infections[@B3], [@B4]. Also, the emergence of multidrug-resistant microorganisms (e.g. methicillin-resistant *Staphylococcus aureus*, MRSA) in hospitals and other healthcare institutions has been associated with increased rates of bacterial infections caused by difficult-to-treat pathogens[@B5], [@B6]. An increasing incidence of infections has also been related to the improvement of identification methods of microorganism[@B7].

To our knowledge, there are no comprehensive studies describing the entire spectrum of osteomyelitis in Southwest China. Thus, our objective was to examine the epidemiological, clinical and microbiological characteristics of osteomyelitis in a hospital that serveing for mainjority of this area over a four-year period from January 1, 2012 to December 31, 2015.

Materials and Methods
=====================

This study was a hospital-based investigation conducted at Affiliated Hospital of Zunyi Medical College, China, which was an investigational site participating in the AO Trauma Clinical Priority Program (AOCPP). The Ethics Committee of Affiliated Hospital of Zunyi Medical College approved all the human subject research.

We retrospectively reviewed the records of patients from January 1, 2012 to December 31, 2015, to identify osteomyelitis patients in search of patients with positive wound culture or bone biopsy culture. 84 patients were indentified with confirmed bacterial bone infections and were included in the study. Bacterial susceptibility data was determined by the M-100-S22 protocol (Clinical & Laboratory Standards Institute® (CLSI) 2012 USA. The information collected from patients with osteomyelitis included the patients\' baseline characteristics, clinical presentation, and microbiological records.

Results
=======

We identified 84 patients (58 open fracture cases and 26 closed fracture cases) with post-traumatic osteomyelitis of limb fractures. There were 69 males and 15 females, and the mean age was 43 years (range, 16-72 years).

The medical comorbidities in patients with osteomyelitis are presented in Table [1](#T1){ref-type="table"}. There were 10 identified comorbidities in 84 patients, including compartment syndrome, diabetes, hypertension, hepatic dysfunction, craniocerebral trauma, closed thoracic trauma, osteoporosis, hyperuricemia, hypoproteinemia, and hyperkalemia. The most frequent accompanying conditions were compartment syndrome (4, 18.18%), diabetes (4, 18.18%) and hypertension (3, 13.64%).

The distribution and percentage of affected sites of the 84 patients with osteomyelitis are shown in Table [2](#T2){ref-type="table"}. 66 (78.57%) cases were monomicrobial, and 18 (21.43%) cases were polymicrobial. The most commonly involved site was the tibia-fibula (40, 47.62%), including monomicrobial (32, 38.10%) and polymicrobial (8, 9.52%), femur (20, 23.81%) and radius-ulna (11, 13.10%).

According to the proportion and cases of Gram-positive/negative bacteria (Table [3](#T3){ref-type="table"}), there were 104 strains in 84 patients; 56 (53.85%) strains were Gram-positive bacteria and 48 (46.15%) were Gram-negative bacteria. The most prevalent Gram-positive bacteria were *S. aureus* (39, 37.50%) and*S. epidermidis*(6, 5.77%), and *E. coli* (16 cases, 15.38%) and *Enterobacter cloacae* (11 cases, 10.58%) were the most commonly identified Gram-negative bacteria. Overall, *S. aureus*was the most common pathogen in both monomicrobial (31, 46.97%) and polymicrobial (8, 44.44%) cases, and the breakdown of the 39 strains included MRSA (17, 43.59%) and MSSA (22, 56.41%). The mixed mix infection and pathogenic bacteria are listed in table [4](#T4){ref-type="table"}. The *S. aureus* and *S. epidermidis* strains were sensitive to ampicillin, synercid/ dalfopristin, linezolid, tigecycline, macrodantin, and vancomycin, respectively (Table [5](#T5){ref-type="table"}). All 17 cases of MRSA infection were sensitive to Imezolid, ampicillin, synercid/ dalfopristin, linezolid, tigecycline, furadantin, piperacillin/yaz, rifampicin, and vancomycin, respectively (Table [6](#T6){ref-type="table"}). *E. coli*and *E. cloacae* presented as the main Gram-negative bacteria, and were all sensitive to thienamycin (Table [7](#T7){ref-type="table"}).

Discussion
==========

To the end of understating the incidence and clinical aspects of post-traumatic osteomyelitis in Southwest China, and deriving an empirical antibiotic regimen, we conducted a retrospective analysis of this population. The results showed that the overall rate of post-traumatic osteomyelitis of limb fractures (1.56%) seen at the Affiliated Hospital of Zunyi Medical College is lower than the national average rate (2.6-7.8%) for major medical centers in China[@B8]. This may be associated with our strict screening criteria. The majority of patients with osteomyelitis were young males, and 58 (69.05%) with open fractures. The most commonly involved site was the tibia-fibula (40, 47.62%), which may be related to the fact that these fractures are usually caused by direct trauma, and many of them are open fracture cases. Additionally, open fracture wounds are often contaminated, have long exposure times, and suffer from major soft tissue defects. At the same time, some patients have comorbidities that may delay wound healing, such as compartment syndrome, and diabetes[@B9],. These factors markedly increase the risk of infection[@B10], [@B11].

Two decades ago, Gram-negative bacteria were the main pathogens responsible for osteomyelitis in China. Since then, *S. aureus* has become the most prevalent bacteria in nosocomial infections[@B12]. In this study, we found that the detection rates of MSSA and MRSA were 69.64%, 43.59%, respectively, which compares with the Chinese national average of 59.1% and 57.8%[@B13]. There are regional characteristics for osteomyelitis; in the Southwest region of China, the main strains of MRSA were ST239-III-t30, ST239-037 and ST5-II-t002. In addition, we identified ST5-II, ST59-IV (a community acquired strain) and unique ST2582-III-t030 strains.

Although multidrug resistance is a major healthcare problem[@B14], our research found that all 39 *S. aureus* strains detected were succeptible to imezolid, ampicillin /sulbactam, synercid/dalfopristin, linezolid, tigecycline, furadantin, piperacillin/tazo, and vancomycin. Additionally, all MRSA strains were sensitive to imezolid, ampicillin, synercid/ dalfopristin, linezolid, tigecycline, furadantin, piperacillin/tazo, rifampicin, and vancomycin. MSSA strains were sensitive to imezolid, ampicillin, synercid/ dalfopristin, amoxicillin/clavulanic acid, linezolid, tigecycline, cefoxitin, cefazolin, thiomycin, oxacillin, piperacillin/tazo, and vancomycin. Interestingly, this result differs from the drug-resistant bacteria spectrum observed in other regions in China. Additionally, while we identified common strains (ST 239, ST5, and ST59), we also found osteomyelitis patients infected with ST2582-III-t30, which appears to be unique in Southwest of China.

There are several notable limitations to this study. This is a retrospective study and the size of sample is relatively small. We were not able to save fresh specimens to extract DNA, RNA or protein to complete gene sequencing in order to screen for gene mutation and to confirm the level of protein expression. In addition, our results only represent the osteomyelitis cases seen in Zunyi and its surrounding area. Thus, a large multi-center prospective study would be required to identify determine patient outcomes and to offer a broader assessment of osteomyelitis in Southwest China.

The overall rate of post-traumatic osteomyelitis of limb fractures in Zunyi is lower than the national average of major medical centers in China. The regional characteristics from an epidemiological, clinical and microbiological characteristics are shown by this study. These results can provide guidance for the early diagnosis and treatment including empiric antibiotic therapy for osteomyelitis.
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###### 

Medical comorbidities in patients with osteomyelitis

  Comorbidity                         n
  ----------------------------------- --------
  Osteofascial compartment syndrome   4
  Diabetes                            4
  Hypertension                        3
  Hpatic dysfunction                  2
  Craniocerebral trauma               2
  Closed thoracic trauma              2
  Osteoporosis                        2
  Hyperuricemia                       1
  Hypoproteinemia                     1
  Hyperkalemia                        1
  **Total**                           **22**

###### 

The Distribution and percentage of affected sites

  Infection site     Single infection (%)   Mixed infection (%)   Total (%)
  ------------------ ---------------------- --------------------- -----------------
  Tibia and Fibula   32 (38.10)             8 (9.52)^\*\*^        40 (47.62)
  Femur              13 (15.48)             7 (8.33)^\*\*^        20 (23.81)
  Radius and Ulna    9 (10.71)              2(2.38)^\*\*^         11 (13.10)
  Humerus            5 (5.95)               ---                   5 (5.95)
  Patella            5 (5.95)               ---                   5 (5.95)
  Calcaneus          2 (2.38)               1 (1.19)^\*\*^        3 (3.57)
  **Total (%)**      **66 (78.57)**         **18 (21.43)**        **84 (100.00)**

Notes: The superscript \*\* are mix infection cases which the detail is listed in table [4](#T4){ref-type="table"} Mix infection: Sites and pathogenic bacteria.

###### 

The proportion and cases of the Gram-positive/negative bacteria

  Pathogenic bacteria                      Isolate   Proportion (%)
  ---------------------------------------- --------- ----------------
  **[Gram-positive bacteria]{.ul}**                  
  Staphylococcus aureus^\*\*^              39        37.5
  Staphylococcus epidermidis^\*\*^         6         5.77
  Enterococcus avium^\*\*^                 2         1.92
  Staphylococcus simulans                  1         0.96
  Streptococcus milleri^\*\*^              1         0.96
  Staphylococcus aureus subspecies^\*\*^   1         0.96
  Staphylococcus hominis^\*\*^             1         0.96
  Enterococcus faecalis ^\*\*^             5         4.81
  **[Gram-negative bacteria]{.ul}**                  
  Escherichia coli^\*\*^                   16        15.38
  Enterobacter cloacae^\*\*^               11        10.58
  Klebsiella pneumoniae^\*\*^              4         3.85
  Pseudomonas aeruginosa^\*\*^             4         3.85
  Citrobacter koseri                       2         1.92
  Serratia marcescens                      1         0.96
  Morganella morganii                      2         1.92
  Baumann acinetobacter^\*\*^              6         5.77
  Klebsiella oxytoca \*\*                  1         0.96
  Basillus ^\*\*^                          1         0.96
  Total                                    104       100

Note: The superscript \*\* are mix infection cases which the detail is listed in table [4](#T4){ref-type="table"} Mix infection: Sites and pathogenic bacteria.

###### 

Mix infection: Sites and pathogenic bacteria

  Sites                      Case No.                Pathogenic bacteria                                 
  -------------------------- ----------------------- --------------------------- ----------------------- --
  Tibia and Fibula (44.4%)   1                       S.aureus                    Klebsiella pneumoniae   
  2                          S.aureus                Pseudomonas aeruginosa                              
  3                          S.aureus                Streptococcus epidermidis   S. Hominic              
  4                          S.aureus                Streptococcus milleri                               
  5                          S.aureus subspecies     Psiudomonas aeruginoso                              
  6                          S. epidermidis          Basillus                                            
  7                          Enterobacter cloacae    Baumann acinetobacter                               
  8                          Enterobacter cloacae    Klebsiella oxytoca                                  
  Femur (38.9%)              9                       S.aureus                    Baumann acinetobacter   
  10                         S.aureus                Escherichia coli            Baumann acinetobacter   
  11                         S. epidermidis          Enterococcus faecali                                
  12                         Enterococcus avium      Escherichia coli                                    
  13                         Enterococcus faecalis   Enterobacter cloacae                                
  14                         Eschrichia coli         Baumann acinetobacter                               
  15                         Eschrichia coli         Baumann acinetobacter                               
  Radius and Ulnar (11.1%)   16                      S.aureus                    Enterobacter cloacae    
  17                         S.aureus                Pseudomonas aeruginosa                              
  Calcaneus (5.60%)          18                      Enterococcus faecalis       Escherichia coli        

###### 

The rate of drug resistance of the main Gram-positive bacteria

  Antibiotics              S.aureus (n=39)           S. epidermidis (n=6)       
  ------------------------ ----------------- ------- ---------------------- --- -------
  Penicillin               29                74.36                          6   100
  Erythrocin               24                61.54                          3   50
  Lincomycin               22                56.41                          5   83.33
  Tetracycline             21                53.85                          4   66.67
  Oxacillin                17                35.9                           5   83.33
  Cefoxitin                17                35.9                           3   50
  Levofloxacin             6                 15.38                          3   50
  Inducible clindamycin    6                 15.38                          2   33.33
  Co-trimoxazole           4                 10.26                          3   50
  Ciprofloxacin            4                 10.26                          2   33.33
  Moxifloxacin             2                 5.13                           1   16.67
  Rifampicin               1                 2.56                           2   33.33
  Vancomycin               0                 0                              0   0
  Tigecycline              0                 0                              0   0
  Synercid/ Dalfopristin   0                 0                              0   0
  Macrodantin              0                 0                              0   0
  Linezolid                0                 0                              0   0
  Ampicillin               0                 0                              0   0

###### 

The rate of drug resistance of Staphylococcus aureus

  Antibiotics                   MRSA(n=17)           MSSA(n=22)        
  ----------------------------- ------------ ------- ------------ ---- -------
  Penicillin                    17           100                  22   100
  Erythrocin                    17           100                  7    31.82
  Cefoxitin                     17           100                  0    0
  Oxacillin                     17           100                  0    0
  Lincomycin                    16           94.12                6    27.27
  Tetracycline                  9            52.94                13   59.09
  Levofloxacin                  2            11.76                4    18.75
  Ciprofloxacin                 2            11.76                2    9.09
  Inducible clindamycin         1            5.88                 5    22.73
  Co-trimoxazole                1            5.88                 3    13.64
  Gentamicin                    1            5.88                 3    13.64
  Moxifloxacin                  1            5.88                 1    4.55
  Amoxicillin/Clavulanic acid   1            5.88                 0    0
  Cefazolin                     1            5.88                 0    0
  Thiomycin                     1            5.88                 0    0
  Rifampicin                    0            0                    1    4.55
  Imezolid                      0            0                    0    0
  Ampicillin /sulbactam         0            0                    0    0
  Synercid/ Dalfopristin        0            0                    0    0
  Linezolid                     0            0                    0    0
  Tigecycline                   0            0                    0    0
  Furadantin                    0            0                    0    0
  Piperacillin/Tazo             0            0                    0    0
  Vancomycin                    0            0                    0    0

###### 

The rate of drug resistance of the main Gram-negative bacteria

  Antibiotics        E. coli (n=16)           Enterobacter cloacae (n=11)        
  ------------------ ---------------- ------- ----------------------------- ---- -------
  Ampicillin         14               87.5                                  10   90.91
  Cefazolin          14               87.5                                  7    63.64
  Sulbactam          12               75                                    10   90.91
  Ceftriaxone        11               68.75                                 5    45.45
  Levofloxacin       11               68.75                                 4    36.36
  Ciprofloxacin      9                56.25                                 4    36.36
  Co-trimoxazole     9                56.25                                 3    27.27
  ESBL               9                56.25                                 2    18.18
  Aztreonam          6                37.5                                  5    45.45
  Ceftazidime        6                37.5                                  5    45.45
  Gentamicin         6                37.5                                  5    45.45
  Cefepime           5                31.25                                 4    36.36
  Cefotetan          1                6.25                                  8    72.73
  Amoxicillin        1                6.25                                  3    27.27
  Nitrofurantoin     0                0                                     6    54.55
  Tobramycin         0                0                                     5    45.45
  Piperacillin       0                0                                     4    36.36
  Amikacin           0                0                                     4    36.36
  Erythrocin         0                0                                     3    27.27
  Piperacilin/Tazo   0                0                                     3    27.27
  Ertapenem          0                0                                     2    18.18
  Thienamycin        0                0                                     0    0
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